BioSpace News Archive

Immunovant, Inc., a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at an offering price of $6.00 per share.

Viveve Medical, Inc. announced the Company received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application 16/454,578 covering Viveve’s unique dual-energy treatment to address SUI in women.

InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, announced the appointment of Jason Myers, Ph.D., and Carol Berry to the company’s Board of Directors.

Ampio Pharmaceuticals, Inc. received written notification from NYSE American LLC stating that the staff of NYSE Regulation has determined to commence proceedings to delist the Company’s common stock from the Exchange.

Stryker announced the launch of the Monterey AL Interbody System, a stand-alone interbody fusion device designed for anterior lumbar interbody fusion.

AXIM Biotechnologies, Inc. announced that it has received an initial order of 19,000 point-of-care diagnostic tests and 100 readers targeting ocular surface diseases through its exclusive global commercialization partner Verséa Ophthalmics, LLC, marking the Company’s first large-scale revenue generating order.

GBS Inc. announced it has acquired Intelligent Fingerprinting Limited, thus expanding the GBS platform of rapid, non-invasive diagnostic testing technologies.

Xosomix, a pre-clinical drug discovery company focused on harnessing diagnostic and therapeutic use of exosomes, the critical communication and transport mediators of the body, announced the awarding of phase I SBIR grant from Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Personalis, Inc. has joined with Duke University and Olink Proteomics AB to form a research collaboration to study the effects of immunotherapy on advanced gastroesophageal cancer.

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, has appointed Tony Collins as its new Chief Financial Officer.